(-0.03%) 5 477.00 points
(-0.07%) 38 791 points
(0.02%) 19 926 points
(0.25%) $80.53
(1.29%) $2.82
(0.16%) $2 332.70
(-0.33%) $29.30
(-0.22%) $968.80
(0.01%) $0.932
(-0.15%) $10.64
(0.05%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy...
Stats | |
---|---|
Šios dienos apimtis | 188 079 |
Vidutinė apimtis | 1.40M |
Rinkos kapitalizacija | 5.43M |
EPS | $-0.610 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.550 ) 2024-08-12 |
Last Dividend | $18 491 ( 2008-04-23 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.110 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00200 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-28 | Dewitt Sheila | Buy | 0 | |
2024-02-22 | Tucker Joseph Edward | Buy | 100 000 | Common Stock |
2024-02-22 | Facchini Peter J. | Buy | 50 000 | Common Stock |
2024-02-22 | Coveney Kevin Michael | Buy | 60 000 | Common Stock |
2023-09-15 | Pasqualone Frank | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 80 transactions |
Buy: 11 099 470 | Sell: 332 443 |
Tūris Koreliacija
Enveric Biosciences, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Enveric Biosciences, Inc. Koreliacija - Valiuta/Žaliavos
Enveric Biosciences, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-408 030 (0.00 %) |
EPS: | $-8.02 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-408 030 (0.00 %) |
EPS: | $-8.02 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-435 201 (0.00 %) |
EPS: | $-12.77 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-103.50 |
Financial Reports:
No articles found.
Enveric Biosciences, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $18 491 | 2008-04-23 |
Last Dividend | $18 491 | 2008-04-23 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $18 491 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $18.00 | 0.05% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
23 Apr 2008 | $18 491 | 07 Apr 2008 | 15 Apr 2008 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -23.30 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.704 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.43 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.48 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.88 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.68 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -3 201.70 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.89 | 2.00 | -0.963 | -1.925 | [0 - 30] |
freeCashFlowPerShareTTM | -2.89 | 2.00 | -1.444 | -2.89 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.412 | 1.000 | 6.46 | 6.46 | [0.2 - 0.8] |
operatingProfitMarginTTM | -21.74 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0731 | 0.800 | -2.85 | -2.28 | [0.5 - 2] |
Total Score | -2.97 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.196 | 1.000 | -0.121 | 0 | [1 - 100] |
returnOnEquityTTM | -3.43 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.89 | 2.00 | -0.963 | -2.89 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.89 | 2.00 | -0.963 | -1.925 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.000590 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -17.86 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.90 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.